Dow Hits New High: JPMorgan, RH, Insulet In Buy Zones From Rebounds

TL;DR

Major indexes reach new highs, but caution is advised as growth stocks could experience a pullback. JP Morgan reports strong earnings, while RH and Insulet show rebounding patterns.

Transcript

good afternoon from Los Angeles and welcome to stock market today today is Tuesday January 14th and on today's show we're gonna be taking a look at JP Morgan RH as well as insolate but first we need to take a look at the major indexes and because we did finish the session narrowly mixed the Dow up about 1/10 of a percent while the NASDAQ and S&P 50... Read More

Key Insights

• ✋ Major indexes reached new highs, indicating a positive market trend.
• 🦔 Caution is advised as growth stocks could experience a pullback, requiring the need to hedge or weed out weaker stocks.
• 🤝 JP Morgan reported strong earnings and revenue, benefiting from the improved economy due to the China trade deal.
• 🎁 RH and Insulet show rebounding patterns, presenting potential investment opportunities.
• 🇧🇮 Bank stocks, including JP Morgan, may have shorter-term runs and tend to move in line with the SNP or lag a bit.
• 💪 Insulet's solid base and strong earnings estimates make it an attractive option in the diabetes product industry.
• 😷 The medical products industry group has produced many strong names, including Insulet.

Questions & Answers

Q: What are the risks of the major indexes reaching new highs?

While major indexes are hitting new highs, growth stocks may experience a pullback. It is important for investors to pay attention to market signals and be prepared for different scenarios.

Q: Is JP Morgan a good investment option after its strong earnings report?

JP Morgan's stock has already been performing well, and bank stocks tend to have shorter-term runs. While the stronger economy due to the China trade deal may benefit bank stocks, investors should be aware that bank stocks tend to move in line with the SNP or even lag a bit.

Q: Is RH a good investment opportunity after its rebound off the 10-week line?

RH has shown a rebound off the 10-week line, but it is important to consider that this is the third pullback, which may indicate weaker strength. It could be a good opportunity for swing trades or to add shares to existing positions, but not for building a long-term position.

Q: Is Insulet a good buy based on its solid base and strong earnings estimates?

Insulet is nearing a potential buy point from a tight base and has rebounded from the 50-day and 10-week line. While it is actionable now, investors could wait for it to go another half percentage point above the buy point. The diabetes product industry has shown positive trends, making Insulet an attractive option.

Summary & Key Takeaways

• Major indexes, including the Dow, NASDAQ, and S&P 500, finished narrowly mixed after reaching new highs.

• Growth stocks may experience a pullback, highlighting the need to hedge or weed out weaker stocks.

• JP Morgan reports strong earnings and revenue, while RH and Insulet show rebounding patterns in their weekly charts.